The capital total is a staggering 46% increase from its last set of funds, closed in May 2021 at $1.3 billion. OrbiMed and Fidelity Management and Research Co., however, participated in Adagios Series A, B and C rounds. The below analyses are based on Evaluate Pharmas venture financing data, with a specific focus on drug developers. Largest investment: 9.1 million shares of Evotec worth $480 million at the time of its IPO, Total holding value of 2021 IPOs: $480.4 million. The largest deal of 2021 was the transaction of Treeline Biosciences (USD 735m), while the most active investor was Alexandria Venture Investments with 51 investments in 2021. The Indian startup/ VC ecosystem will truly come of age Partner Ernst Theodor Sack, Vaughn Blake, Robert Macinnis, PH.D. SoftBank, based in Tokyo, has a reputation for placing large bets on bold ideas. Asia Pacific ; Just eight months into this new SPAC phenomenon, weve already seen signs of oversaturation in the market, with a recent uptick in the number of downsized SPAC IPOs, PitchBook analysts said. Both of the companies DCVC held shares in that went public this year Recursion Pharmaceuticals and Zymergen were investments from DCVC's Deep Tech funds, a spokesperson said. Also includes one tools & services company, Rapid Micro Biosystems, which focuses on detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. Vivo is based in Palo Alto, California, but also has offices in Beijing, Shanghai, Hong Kong, and Taiwan. Vivo is a healthcare-focused VC firm with $5.8 billion in assets under management. Octopus Ventures is a London and New York based venture capital firm, focused on backing unusually talented entrepreneurs. Additionally, Bain Capital Crypto closed a $500 million fund in March 2022, and the firm announced a $2.4 billion Tech Opportunities fund earlier this month. Research. The firm seeks to invest in seed-stage, early-stage, and later-stage companies. It is typical for venture capital firms to identify and back companies in As per Forbes, Biopharma mergers generated a further $37 billion. Largest investment: 53.8 million shares of LianBio worth $861 million at the time of its IPO, Total holding value of 2021 IPOs: $1.2 billion. WebThe 45 most important VCs in Texas, according to other VCs. Early Stage VC, Later Stage VC, PE Growth/Expansion, Seed Round. With a strong M&A environment for exits, venture capitalists continue to fuel biotech industry growth. Apparel and Accessories, Beverages, Consumer Durables, Food Products, Healthcare, Other Restaurants, Hotels and Leisure, Services (Non-Financial), Software, Co-founders and General Partners Genevieve Gilbreath and Dan Graham. (12), Current fund: 250 million ($310 million) Highland Capital Growth Fund, closed in May; and the $400 million Highland Capital Partners IX L.P., closed 2013. The firm seeks to invest in seed-stage, early-stage and later-stage companies. It has $3.7 billion in assets under management, a spokesperson said. Boston Cambridge Massachusetts Consistently, the top state for biotechnology industries in Massachusetts, particularly in the Greater Boston area. It has $130 million in a SPAC and is looking for a healthcare company to acquire. PitchBook has published its 2021 U.S. Venture Capital Outlook report. The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Mercks venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. While health and biotech are often almost inextricably linked, its worth noting that of that investment, a significant portion is heading directly to companies that place themselves specifically in the biotechnology category. Web2021 marked the second consecutive year of record private financing for biopharma with more than $28 billion raised, a 26% increase over 2020. Who has the most invested in funding up-and-coming biotechs? Knowing a venture capital firms investment portfolio is crucial before contacting them. The firm is headquartered in San Francisco, California. (9), Current biopharma portfolio companies: CoMentis, Egalet, Epsilon 3 Bio, FF Pharma, GenSight Biologics, GlycoVaxyn, Levicept, Minerva Neurosciences, Molecular Partners, Novocure, Oncoethix, Sequenta, Versartis, XO1, Year established: 1996; successor to Index Securities, founded 1976, City (cities) where offices are located: Boston; Waltham, MA; San Francisco; Dublin; Also, @dogpatchlabs location in Dublin for biotechnology and technology startups, Fund size and status: About $4 billion under management across seven funds (10), Current fund: $450 million Polaris Venture Partners VII, closed Nov. 24; firm says on its website it continues to invest its sixth fund, $375 million Polaris Venture Partners VI, closed 2010 (10), Current biopharma portfolio companies: 480 Biomedical, Acceleron Pharma, Adimab, Advion, AgBiome, Alector, Alimera Sciences, Arsanis Biosciences, Arsenal Medical, aTyr Pharma, Cerulean Pharma, Editas, Fate Therapeutics, Genocea Biosciences, Hydra Biosciences, Ironwood, Kala Pharmaceuticals, KinDex Pharmaceuticals, Navitor Pharmaceuticals, NextCODE, Ocular Therapeutix, Promedior, Pulmatrix, Receptos, Scholar Rock, Selecta Biosciences, T2 Biosystems, Trevena, Visterra, Xtuit Pharmaceuticals, City (cities) where offices are located: Cambridge, MA; New York; Menlo Park, CA; So Paulo, Brazil; Herzliya Pituach, Israel; Bangalore, India, Fund size and status: More than $4 billion under management across eight funds (11), Current fund: $1.6 billion Bessemer Venture Partners VIII, closed 2011 (11), Current biopharma portfolio companies: Acceleron Pharma, AffyMax, Allena Pharmaceuticals, Cerulean Pharma, Flex Pharma, On-Q-ity, OvaScience, Oxagen, Proteon Therapeutics, Transave Inhalation Biopharmaceuticals, Verastem, City (cities) where offices are located: Cambridge, MA; Palo Alto, CA; Shanghai; London; and Geneva, Fund size and status: $4.2 billion under management across 12 funds. ENT Biotech Solutions is a Michigan-based venture company that develops a novel medical device created by a practicing Otolaryngologist to remove tonsils/adenoids and soft tissue. Angermayer, who is also a movie producer, is especially interested in trying to develop psychedelics into medicines, with investments in ATAI Life Sciences and Compass Pathways, both of which focus on mental health. Over $14 billion was invested in Biopharma startups globally in 2022, with 37 notable IPOs of VC-backed Biotech enterprises raising a total of $4.2 billion. Abogen Biosciences Co., Ltd. Headquarters: Suzhou Abogen Biosciences makes it on this list by virtue of an impressive $700 million Series C round that it bagged in August 2021 one of the biggest-ever private biotech funding rounds. The Indian startup/ VC ecosystem will truly come of age Blume Ventures Blume Ventures is an early-stage and seed-stage venture fund that has its headquarters in Mumbai, Maharashtra, India. 14On June 27, KPCB submitted Form D filings with the U.S. Securities and Exchange Commission disclosing plans to raise an early-stage growth fund of $450 million, known as KPCB XVI, as well as a later-stage fund of $750 million known as KPCB Digital Growth. CEO: John Doerr (chairman), Brook Byers (founder). Insider analyzed corporate filings to identify the venture-capital firms that shaped these biotechs and are positioned to build on their success in 2022. VC investment in the biopharma space is likely to surpass $20 billion in 2021, driven by the need to fund trials and build out research and development programs, as clinical trials resume and elective procedures restart. (1), Current biopharma portfolio companies: Adamas, Balance Therapeutics, CardioDx, Crescendo Bioscience, DVS Sciences, Pacific Biosciences, Personalis, RainDance Technologies, Sequenta, City (cities) where offices are located: Seattle and Menlo Park, CA, Fund size and status: More than $2 billion under management across seven funds, Current fund: $377 million Frazier Healthcare VII, closed 2013, Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Cidara Therapeutics, Collegium Pharmaceutical, Portola Pharmaceuticals, QuatRx Pharmaceuticals, Rempex Pharmaceuticals, Semnur Pharmaceuticals, Silvergate Pharmaceuticals, Tobira Therapeutics, VentiRx Pharmaceuticals, #14 (tie). In a handful of instances, figures and facts came from biographies of the firms principals available on the websites of investee companies and publicly available investor presentations posted online. ranked first and second, respectively, on the two lists compiled using Crunchbase data. In addition to its private-equity investing, RA Capital has brought companies public through SPACs with mixed results. The firm and its SPAC partner, General Catalyst, have until March 2023 to find a company to acquire or return the money to investors. This information is up to date through 2009 - an incredibly difficult year for bio-tech companies to raise venture capital funding, as the financial crisis caused investing firms to become more cautious with their money, but many companies manage to attract VC investments in even in the toughest economic conditions. But it had holdings in nine biotech companies that went public this year, including Vor Biopharma, Omega Therapeutics, and Adagio Therapeutics. Biotech Venture Capital Firms: Top Venture Capital Firms. Venture capital in U.S. and Europe biotechnology industry 2015-2021 U.S. bioscience venture capital investments by segment 2018-2021 biotechnology funding by National Institutes for Health 2013-2023 Jan 6, 2023 12:43pm. That seventh fund closed $50 million higher than the $400 million offering amount that the firm stated back on June 17, when it disclosed its plan to raise the fund in a Form D filing with the U.S. Securities and Exchange Commission. With the global venture capital investment market size reaching US$ 233.9 Billion in 2022, you might be wondering who the industry's biggest players are. Neoteny Co., Ltd was founded on December 1999 and is based in Tokyo, Japan.. However, the situation has tremendously changed since the market crash began in November 2021. The company is steadily growing its life science footprint, emphasizing infrastructure, financial instruments, and real estate. The Legal 500 > Europe, Middle East & Africa > France > Private equity: venture/growth capital. Founded in 2017, Active Capital is a venture capital firm based in San Antonio, Texas. Largest investment: 18.2 million shares of Adagio Therapeutics worth $46.9 million at the time of its IPO, Total holding value of 2021 IPOs: $468.7 million. WebMarket-leading rankings and editorial commentary - see the top law firms & lawyers for Private equity: venture/growth capital in France. The list is ordered starting with the companies who invested the most in biotechnology. Year established: Established 1993 as Schroder Ventures Life Sciences. Partners & Co-Founders Brad Bentz, Danielle Weiss Allen and Chris Shonk. Our research shows that VC companies invested in 2,200 biotech start-ups worldwide in 2016; by 2021, that number had grown to 3,100. This years list shows the upward progression of VC firms; the lowest-ranked of this years firms had $1.25 billion under management, compared with more than $1.1 billion for the Top 30 Venture Capital Firms of 2013. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! Here is a list of the most active most active bio-tech, pharma and life science investors. With the unprecedented growth in the global Biopharma and MedTech industries, new start-ups with novel ideas are emerging. Below is this years GEN list of 20 top venture capital firms, and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active committed capital from funds in use. The companys life science and healthcare investment portfolio spans the Biopharmaceutical, Biotechnology, medical equipment, services, and information and technology industries. In 1999, Versant Ventures, Inc., a Menlo Park, California-based venture capital company, was founded. Flagship, based in Cambridge, Massachusetts, is more of a venture-creation firm than a traditional VC it often creates the companies it invests in. Boston-based. Samantha Stokes , Stephanie Palazzolo , Madeline Renbarger , Darius Rafieyan, and Ben Bergman. Flagship Pioneering offers a distinctive business strategy that conceives, develops, finances, and expands first-in-category ventures to revolutionize sustainability and human health. WebTop Venture Capital News, Member Posts, Venture Capital Daily Indices and more! The firm seeks to invest in the media, software, and healthcare sectors. As a spin-off of the Sprout Group, NLVP has been participating in Biopharma since 2005. Polaris isnt alone. If investment continues at the current pace, 2022 could likely top 2020 for total funding. 1 We also found that biotech Founded in 2014, ATX Venture Partners is a US-based venture capital firm that focuses on seed, series A and early-stage B2B software investments, usually with a Texas-centric geographic focus. DCVC, based in Palo Alto, California, invests in what it considers "deep tech," so many of the biotech companies it gets involved with are focused on sequencing, artificial intelligence, and other data-driven approaches to healthcare. New Leaf Venture Partners (NLVP) invested in Biopharmaceuticals during its growth and venture phases. It closed its second Xontogeny-focused fund in May, giving it another $515 million to invest in a dozen or more companies. It is owned entirely by the Novo Nordisk Foundation, the holdings limited of the Novo Group. Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch. Latest biotech merger sees aimless Adamis snapped up by DMK - FierceBiotech 4h ago Asia Pacific ; Fierce Healthcare. See: http://www.sec.gov/Archives/edgar/data/1612343/000161234314000001/xslFormDX01/primary_doc.xml VC activity in biotechs grew by 45 percent in a year, taking the 2020 global total to $36.6 billion. WebMarket-leading rankings and editorial commentary - see the top law firms & lawyers for Private equity: venture/growth capital in France. Business Products and Services (B2B), Consumer Products and Services (B2C), Financial Services, Information Technology, Materials and Resources. 7 On May 29, partners submitted a Form D stating their intent to raise a $380 million sixth fund, to be named MPM BioVentures 2014. The business focuses on disruptive and clinically significant technologies with a long tradition of curative Biopharma investments and a recent focus on expanding digital health investments. CipherBio data reveals that the US is an undisputed leader in life science space as the location attracting most of the Biotech funding since the beginning of 2019 69% of all deals closed in the top 10 locations globally accounts for the US (Figure 2). Urban Capital Network is a venture capital firm based in Houston, Texas. In 2022, over $14 billion was funded in Biopharma setup globally, and 37 major IPOs of VC-backed Biotech businesses raised a combined $4.2 billion. The top 10 biotech IPOs of 2021 | Fierce Biotech. It's structured as five teams with different investment focuses, investing in both tiny biotech startups and established biopharma companies. (Reuters) - The two main areas for venture capitalist (VC) investment - technology and healthcare - have grown during the COVID-19 pandemic and investors have ample dry powder to direct money at biotech and pharma firms in 2021, research firm PitchBook said on Monday. Largest investment: 30.3 million shares of ATAI Life Sciences worth $455 million at the time of its IPO, Total holding value of 2021 IPOs: $481.9 million. Current biopharma portfolio companies: Hyperion Therapeutics, OpGen, City (cities) where offices are located: Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel, Fund size and status: $4.2 billion under management across nine funds, Current fund: $675 million Canaan Partners X, announced Oct. 16, Current biopharma portfolio companies: Aldea Pharmaceuticals, Arvinas, Axial Exchange, Chimerix, Chrono Therapeutics, CytomX, Dermira, Durata Therapeutics, Envisia Therapeutics, LQ3 Pharma, Marinus Pharmaceuticals, Novira Therapeutics, Sample6, Semnur Pharmaceuticals, Spinifex Pharmaceuticals, Theraclone Sciences, Tobira Therapeutics, VaxInnate, City (cities) where offices are located: New York; San Francisco; Mumbai; Shanghai; Herzliya, Israel, Fund size and status: Approximately $12 billion under management in five public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to invest in healthcare royalty streams, Current fund: $325 million OrbiMed Asia Partners II, closed September; $735 million OrbiMed Private Investments V, closed October 2013, Current biopharma portfolio companies: Acceleron Pharma, Adaptimmune, Aerocrine, Adimab, Aerpio, Affimed, Alector, Amarin, Ambit Biosciences, Anthera, arGEN-X, ARMO BioSciences, Arsanis Biosciences, Arteaus, Audentes Therapeutics, Avitide, Bharat Serums and Vaccines, Biodel, BioLineRx, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Clementia, Dimension Therapeutics, Durata Therapeutics, Eddingpharm, GC-Rise Pharmaceutical, Good Start Genetics, Igenica, Intercept Pharmaceuticals, Invitae, Iroko Pharmaceuticals, Loxo Oncology, Mirati Therapeutics, Otic Pharma, Otonomy, OxOnc Development, PharmAbcine, Pieris, Principia Biopharma, ProNAi, RDD Pharma, RedHill Biopharma, Relypsa, Response BioMedical, Roka BioScience, Sage Therapeutics, Selecta Biosciences, Shasun, singulex, Symbionics Therapeutics, Waterstone Pharmaceuticals, #2. Additionally, Bain Capital Crypto closed a $500 million fund in March 2022, and the firm announced a $2.4 billion Tech Opportunities fund earlier this month. Exclusive Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms By Kate Sheridan Reprints Adobe F lagship Pioneering is on track to Based out of Dhahran (Saudi Arabia), the firm also operates through regional offices in North America and Europe. After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last years levels. Six top firms held more than $1 billion in equity: Arch Venture Partners, Novo Holdings, Flagship Pioneering, RA Capital Management, Perceptive Advisors, and SoftBank. Subscribe to STAT+ for less than $2 per day, Unlimited access to essential biotech, medicine, and life sciences journalism, Subscribe to STAT+ for less than $2 per day, Unlimited access to the health care news and insights you need, My sons time is running out due to a rare disease. The firm seeks investments in seed-stage, early-stage and later-stage companies. See: http://fortune.com/2014/10/02/exclusive-atlas-venture-is-splitting-up/ Largest investment: 16.2 million shares of Theseus Pharmaceuticals worth $259 million at the time of its IPO, Total holding value of 2021 IPOs: $988.4 million. There is mixed news heading into 2021 on the COVID-19 pandemic front, with rising infection levels and a handful of vaccines showing promise. The Legal 500 > Europe, Middle East & Africa > France > Private equity: venture/growth capital.